The Cologne-based biotech will use the funding to scale its rapid “PCR to Go” system for fast, on-the-go pathogen detection.
Cologne-based biotechnology company Detechgene has closed a €3.2 million seed financing round, its second to date, to advance mobile molecular diagnostics. The round was led by neoteq ventures, with participation from NRW.BANK, Aquarius Invest, Meerkat Holding, Campus Capital, and several strategic angels.
Founded to make laboratory diagnostics more accessible, Detechgene is developing “PCR to Go,” a portable molecular biology testing platform designed to detect a wide range of pathogens quickly and reliably at the point of care. The company says its technology delivers lab-standard accuracy in a mobile, user-friendly format.
“Detechgene is tackling a global challenge with a solution that’s fast, mobile and precise — without compromising on the standards of laboratory diagnostics” said B.J. Park, Managing Partner at neoteq ventures. “What impressed us is not just the technology, but the execution strength of the team.”
Aquarius Invest’s Dr. Christoph Labisch added that the financing “sends a strong signal: Detechgene is bringing molecular diagnostics where it is needed — quickly, accurately and on the go”
Detechgene’s Managing Director, Reza Esmaillie, said the funding will help scale its diagnostics platform: “Together, we are shaping the future of diagnostics — faster, more decentralised and more user-friendly than ever before”
The company sees broad applications for its technology in healthcare systems under strain, aiming to deliver flexible and rapid diagnostic tools both in Germany and internationally.